Alumis and Acelyrin finalise amended merger agreement with improved terms
The merger aims to create a major late-stage clinical biopharma company dedicated to developing and commercialising innovative therapies for immune-mediated diseases

A leading resource for the Pharmaceutical industry since 2002
The merger aims to create a major late-stage clinical biopharma company dedicated to developing and commercialising innovative therapies for immune-mediated diseases
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry